Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325929 | PMC |
| http://dx.doi.org/10.7189/jogh.11.03064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disaster Medicine Core Competencies: Comparative Analysis of Emergency Medicine Residency Training in Taiwan and the United States.
West J Emerg Med
June 2025
National Taiwan University Hospital, Department of Emergency Medicine, Taipei, Taiwan.
Background: Situated in the western Pacific Ocean, Taiwan has faced a diverse array of natural and man-made disasters. Since 2000, disaster medicine education has been progressively integrated into various medical professions, with a focus on training disaster medical assistance teams, managing chemical and radiological emergencies, and enhancing prehospital and hospital emergency management capabilities. Despite the key roles of emergency physicians (EP) as primary responders and crucial managerial personnel during disasters, a comprehensive assessment of the disaster medicine core competencies (DMCC) required for emergency medicine (EM) residency training might serve as a blueprint for Taiwan's EM residency core curriculum.
View Article and Find Full Text PDFUtilization of Evidence Blueprint Initiative to Transform Capability Development in AstraZeneca Spain.
Pharmaceut Med
July 2025
Biopharmaceuticals Medical, AstraZeneca Farmacéutica Spain, Medical Affairs Department, C. del Puerto de Somport 21-23, Fuencarral-El Pardo, 28050, Madrid, Spain.
The role of Medical Affairs (MA) has shifted from traditional evidence dissemination to an integrated process leveraging real-world data (RWD) and diverse data sources. To adapt and lead this shift, AstraZeneca (AZ) Spain recognized the essential need to identify gaps in evidence-generation capabilities and establish targeted strategies aligned with both global and local priorities. The objective of this work was to assess AZ Spain's current evidence-generation capabilities and identify areas for improvement by using the so-called "Evidence Blueprint" framework.
View Article and Find Full Text PDFDiscontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SD.
Target Oncol
July 2025
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5 Street, 02-781, Warsaw, Poland.
Background: The optimal duration of immunotherapy (ITH) remains undefined for patients with metastatic melanoma, and debates on de-escalation strategies are ongoing. Patients in the pivotal KEYNOTE and CheckMate trials who experienced a complete response (CR) on ITH had long-term responses, even after treatment was terminated early because of toxicity or at the physician's discretion.
Objective: Our study explores the duration of planned ITH drug holidays-intentional ITH suspension until disease progression off treatment-in patients with unresectable and metastatic melanoma treated for at least 6 months with ITH.
Do as I say and not as I do: Surgical critical care program directors and diplomates shape the future.
J Trauma Acute Care Surg
June 2025
From the Division of General Surgery, Trauma, and Surgical Critical Care, Department of Surgery (T.J.J., K.A.D.), Yale School of Medicine, New Haven, Connecticut; Psychometrics and Research (C.L.B., C.O.P.), American Board of Surgery, Philadelphia, Pennsylvania; Division of Traumatology, Surgical Cr
Background: In 1987, the Trauma, Burn, Surgical Critical Care Specialty Board of the American Board of Surgery began offering certification in surgical critical care (SCC). The blueprint for the certifying examination (CE) has changed little since then. The Trauma, Burn, Surgical Critical Care Specialty Board sought to modernize the content of the CE.
View Article and Find Full Text PDFCirculating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.
Target Oncol
July 2025
Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, HPC AA11, Postbus 30.001, 9700RB, Groningen, The Netherlands.
Background: High-dose osimertinib shows modest anti-tumor activity and acceptable toxicity in patients with advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor exon 20 mutation (EGFRex20+). Plasma-derived circulating tumor DNA (ctDNA) is promising in monitoring responses and detecting resistance mechanisms to therapy.
Objective: We aimed to assess the concordance between variants detected in ctDNA to those found in corresponding tissue samples at baseline and progression, to analyze alterations in mutant ctDNA levels of EGFRex20+ variants as predictors of therapy response, and to identify resistance mechanisms to high-dose osimertinib as well as examine changes in mutant ctDNA levels of EGFRex20+ variants.